ShareValue.ai

ShareValue scores for BHC: Valuation 65, Quality 70, Growth 56, Health 29.

BHC
NYSE

Bausch Health Companies Inc

$4.76(-9.85%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
65
Fair Value
Price vs Value
Quality
70
Strong
Business Strength
Growth
56
Moderate
Revenue & Earnings
Health
29
Stressed
Financial Stability
Momentum
42
Neutral
Price Trend

Company Details

About

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026